The study, meticulously compiled by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington alongside a broad network of international collaborators, integrates data from over a thousand novel sources and applies advanced modeling methodologies. This comprehensive approach allows for granular insights into maternal mortality trends across 204 countries and territories, including detailed subnational analysis for twenty nations. The robustness of the dataset reveals stark regional disparities, with maternal deaths disproportionately concentrated in sub-Saharan Africa, parts of Oceania, South Asia, and regions of the Caribbean. Countries such as Nigeria, India, the Democratic Republic of the Congo, Ethiopia, and Pakistan emerge as epicenters for maternal mortality, each contributing substantially to the global burden.

Analyzing progress from 1990 to 2023 shows encouraging historical reductions, with the maternal mortality ratio falling from 321 to 191 per 100,000 live births. Notably, the period from 2000 to 2015 experienced rapid annual declines of nearly 3%, attributed largely to international health initiatives and expanded access to maternal healthcare. However, the trajectory sharply diverges post-2015, as the decline has slowed to an anemic average of 0.5% per year. Alarmingly, certain nations have even witnessed increases in maternal mortality ratios during this latter period, a trend that threatens global progress and raises questions surrounding healthcare system resilience and equity.

The regional distribution of maternal mortality ratios remains uneven. Sub-Saharan Africa continues to bear the heaviest burden, with countries such as Liberia, the Central African Republic, Haiti, Eritrea, and Sierra Leone recording maternal mortality ratios exceeding 700 deaths per 100,000 live births. These figures starkly illustrate persistent systemic challenges, including under-resourced health infrastructure, shortages of skilled birth attendants, and limited emergency obstetric care. The Caribbean and Oceania regions also register high maternal mortality rates, highlighting the need for targeted regional health policy interventions.

Examining the underlying causes of maternal mortality reveals that the majority are attributable to preventable conditions. Maternal hemorrhage and hypertensive disorders during pregnancy account for more than 40% of these deaths globally. These findings emphasize the critical importance of improving access to quality antenatal care, skilled delivery services, emergency obstetric treatment, and postnatal follow-up. Health systems must prioritize the continuum of care before, during, and after pregnancy to mitigate avoidable complications and avert maternal fatalities.

The study underscores that data quality and availability remain substantial barriers to effective maternal health interventions, particularly in high-burden, low-resource regions. Many countries lack comprehensive vital registration systems and maternal death surveillance mechanisms, which diminishes the accuracy of maternal mortality estimates and hampers timely policy responses. Strengthening health information systems and expanding high-quality data collection frameworks are indispensable for enabling tailored and dynamic health policies that can adapt to evolving maternal health challenges.

Socioeconomic factors profoundly influence maternal mortality outcomes, intertwining health system capacity with broader social determinants of health. Economic growth and expansion of healthcare resources have correlated with reduced maternal deaths in several contexts. Nevertheless, countries like Ethiopia, Bangladesh, Nepal, and Cambodia have demonstrated that marked improvements can occur even in resource-constrained settings through strategic investments in facility-based deliveries and maternal health service scaling. These case studies provide valuable lessons in leveraging limited resources for maximal health impact.

The COVID-19 pandemic introduced an unprecedented disruption to maternal health progress. Early in the pandemic, before widespread vaccine availability, increased infection rates led to a spike in maternal deaths in select regions. Latin America, parts of the Caribbean, Central and Eastern Europe, and high-income North America experienced temporary reversals in maternal mortality reduction, driven by both direct effects of COVID-19 infection in pregnant women and indirect consequences of healthcare system strain. This wave of adversity highlighted vulnerabilities within maternal health programs and underscored the interconnectedness of pandemic preparedness and maternal health resilience.

Despite the transient setbacks engendered by the pandemic, many countries with robust health systems demonstrated resilience, returning maternal mortality trends towards pre-pandemic trajectories by 2022 and 2023. However, this recovery is uneven and fragile. The persisting rates of maternal death remain unacceptably high in numerous parts of the world, signaling that the global community still faces profound challenges in achieving the SDG maternal mortality target within the next five years.

Addressing this complex challenge demands renewed international commitment and investment. Policymakers and global health stakeholders must adopt a multipronged strategy prioritizing health system strengthening, equitable access to maternal healthcare, and enhanced surveillance infrastructures. Emphasizing quality of care, especially in the most affected countries, is vital to accelerate reductions in maternal mortality. Additionally, integrating social equity considerations by addressing disparities in gender, socioeconomic status, and geography will be imperative to ensure no woman is left behind.

In conclusion, while global maternal mortality has witnessed historic advances, the current slowdown in progress coupled with persistent high rates in vulnerable regions signals an urgent call to action. Combating maternal mortality necessitates an integrated approach encompassing clinical excellence, robust data infrastructures, health equity, and pandemic preparedness. Meeting the SDG 3.1 target is within reach only through decisive, well-coordinated global efforts that address both the medical and social determinants of maternal health. The window for transformative progress is rapidly narrowing, making immediate and sustained interventions indispensable for saving the lives of hundreds of thousands of women worldwide.

Subject of Research: People
Article Title: Global, regional, and national levels and trends in maternal mortality, progress towards the Sustainable Development Goals, and mortality from COVID-19 infection in pregnant women, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
News Publication Date: 26-Mar-2026
Web References: Not provided
References: DOI 10.1016/S3050-5038(26)00047-6
Image Credits: Not provided
Keywords: maternal mortality, global health, Sustainable Development Goals, SDG 3.1, sub-Saharan Africa, maternal hemorrhage, hypertensive disorders, COVID-19, pandemic impact, health systems, maternal care quality, vital registration

Over the 20-year period, advancements in medical interventions have yielded an average increase of approximately 1.3 healthy years per American life span. This figure, while modest, represents an important improvement in longevity combined with quality of life. However, this health gain came at a considerable cost: an additional $234,000 in lifetime healthcare spending per individual. When calculated from birth, this results in an average expenditure of nearly $182,000 for each extra healthy year gained, a statistic that underscores the escalating financial demands of modern healthcare systems.

The study’s analytical rigor is evident in its cause-specific approach. Researchers meticulously analyzed changes across 132 disease categories, capturing the nuanced interplay between healthcare spending and health outcomes among diverse conditions. This granular perspective allowed for differentiation between conditions where healthcare investments have been highly cost-effective and those where increased spending failed to produce proportional health benefits.

Among the most notable findings is the success story of HIV/AIDS treatment advancements. The introduction of antiretroviral therapies and improved clinical management led to a noteworthy gain of 0.265 healthy years per individual, achieved at a remarkably low increase in lifetime spending—only $2,470. This equates to an exceptional value of about $9,300 per healthy year gained, positioning HIV/AIDS care as one of the most cost-effective domains within the US healthcare landscape.

Ischemic heart disease, a leading cause of mortality and morbidity, also exhibited significant improvements with an added quarter of a healthy year on average. These gains stemmed from enhanced pharmaceuticals, state-of-the-art medical devices, and improved emergency cardiac care systems. The additional expenditure per healthy year gained for ischemic heart disease was approximately $63,000, which, relative to other major health challenges, indicates a favorable return on healthcare investment.

Chronic diseases such as diabetes saw substantial health advances as well, with a 0.234 increase in healthy years. The relatively modest health care spending rise of $6,880 per individual yielded an improved cost-efficiency ratio, around $29,355 per additional healthy year. Investment in chronic disease management likely benefited from the integration of preventive care, patient education, and innovative treatment protocols aiming to reduce long-term complications.

Stroke management showcased extraordinary health value, recording nearly 0.2 extra healthy years gained at an infinitesimal increase of $89 in lifetime healthcare spending per person. This translates into roughly $451 spent per healthy year gained, indicative of the success attributable to improved acute stroke interventions, enhanced rehabilitation protocols, and preventive strategies targeting risk factors.

Conversely, the study also identified areas where healthcare spending grew without corresponding health improvements, or even with declining health outcomes. Drug use disorders exemplify this troubling trend, where HALE decreased by 0.331 years despite a substantial $37,512 increase in lifetime health expenditures per individual. This alarming pattern points to an urgent need for re-evaluation of treatment approaches, policy frameworks, and resource allocation for substance use disorders.

Similarly, chronic kidney disease demonstrated a drop in healthy years by approximately 0.161 despite an increase in health spending, highlighting areas where healthcare innovations have yet to translate into measurable population health gains. The findings emphasize that rising costs alone do not guarantee better health outcomes, a critical insight for stakeholders seeking to optimize healthcare value.

The research further revealed 19 causes of disease where health-adjusted life expectancy improved while lifetime healthcare costs declined, breast cancer being a prominent example. This scenario represents ideal progress, where advancements in screening modalities, less invasive surgical techniques, and targeted therapies have simultaneously enhanced survival and quality of life while reducing overall financial burdens—signaling efficient use of healthcare resources.

In terms of methodological sophistication, the investigation also differentiated between lifetime and age-65 starting points for cost-effectiveness evaluation. The cost per healthy year gained dropped by nearly 50% when calculated from age 65 compared to birth. This dual perspective illuminates the temporal dimension of healthcare investment returns, particularly underscoring how early-life investments in prevention and treatment of chronic conditions like diabetes and cardiovascular disease compound to generate longer-term health dividends.

The authors emphasize that these disease-level spending and outcome estimates form a foundation for more strategic healthcare policy formulation. Instead of sweeping spending cuts, the evidence advocates for nuanced reallocations that channel funds toward disease areas and interventions demonstrating high value—the potential to save lives, enhance quality of life, and maximize the utility of finite healthcare resources.

Prof. Marcia Weaver, the study’s senior author, concludes that aligning healthcare expenditures more effectively with outcomes could dramatically improve the overall value proposition of the US health system. This principle calls for intensified focus on evidence-based allocation, innovation in underperforming areas, and a commitment to health equity to ensure that all Americans benefit from medical advances.

In summary, this landmark analysis convincingly argues that the true metric of healthcare success extends beyond inflation-adjusted spending increases. By closely linking health impact to financial inputs across a spectrum of conditions, the study provides a roadmap for elevating healthcare’s societal value amidst evolving demographic and economic landscapes. Stakeholders, from policymakers to providers, will find this work essential for designing a health system that is not only more effective but also more sustainable.

Subject of Research: People
Article Title: The Value of Healthcare in the United States: Changes in Lifetime Spending and Health-Adjusted Life Expectancy, 1996 to 2016
News Publication Date: February 25, 2026
Web References: https://www.valueinhealthjournal.com/article/S1098-3015(26)00033-1/abstract; http://dx.doi.org/10.1016/j.jval.2026.01.008
Keywords: Health care, Health-adjusted life expectancy, Lifetime healthcare spending, Cost-effectiveness, Chronic diseases, HIV/AIDS, Ischemic heart disease, Drug use disorders, Stroke, Breast cancer, Health policy